Which is better, JSLL.BO or RPRX?

On the Buffett-Fit framework, Jeena Sikho Lifecare Limited (JSLL.BO) currently grades higher than RPRX — 84/100 (A grade) vs 64/100 (C). That said, "better" depends on which framework you trust — JSLL.BO wins on Warren Buffett, Benjamin Graham, Philip Fisher, Peter Lynch, Joel Greenblatt, Charlie Munger, and Terry Smith; RPRX wins on none. The full pillar breakdown is on this page.

Should I buy JSLL.BO or RPRX?

This page is an educational comparison, not investment advice. Both JSLL.BO and RPRX are graded against the same Buffett 5-pillar framework (moat, earnings durability, management quality, financial health, valuation) plus six other documented investor frameworks. Read the side-by-side breakdown to see which one matches the criteria you care about most — and always do your own research before making any investment decision.

Is JSLL.BO better than RPRX for value investing?

On the Buffett-style value-investing framework, JSLL.BO currently grades higher — 84/100 vs 64/100, a 20-point gap. The gap is driven by which pillars each stock passes; the table on this page shows moat, durability, management, financial health, and valuation side-by-side.

What's the difference between JSLL.BO and RPRX on Warren Buffett's framework?

Both stocks are evaluated on the same five pillars: economic moat (durable competitive advantage), earnings durability (consistent profitability), management quality (capital allocation), financial health (conservative balance sheet), and valuation (margin of safety). JSLL.BO currently scores 84/100 (A grade); RPRX scores 64/100 (C grade). The "Where each wins" section on this page breaks down which pillar each stock dominates.

Which has the stronger moat, JSLL.BO or RPRX?

Moat strength is one of the five pillars in the Buffett-Fit score on this page. JSLL.BO and RPRX are each scored on ROIC sustainability, gross-margin durability, and qualitative signals like brand strength, switching costs, network effects, and regulatory barriers. The pillar breakdown on this page shows the moat sub-score side-by-side so you can see which one has the more durable competitive advantage.

Which is more undervalued, JSLL.BO or RPRX?

Valuation is one of the five Buffett-Fit pillars on this page. Both stocks are scored on owner-earnings yield, price-to-intrinsic-value vs the underlying compounding rate, and the margin of safety relative to a conservative DCF. The valuation sub-score in the table below tells you which one currently trades at a more attractive price relative to its underlying business quality.

Are JSLL.BO and RPRX both Healthcare stocks?

Yes — both Jeena Sikho Lifecare Limited (JSLL.BO) and Royalty Pharma plc (RPRX) operate in the Healthcare sector. That makes this a direct sector-peer comparison, which is the apples-to-apples way to use the Buffett-Fit framework: the score weighs each stock against its sector's specific quality and valuation benchmarks (sector-relative bonus), so the cross-stock comparison isn't distorted by inter-sector base-rate differences.

Is this JSLL.BO vs RPRX comparison investment advice?

No. This page is an educational pattern-match against documented public frameworks (Buffett, Graham, Fisher, Lynch, Greenblatt, Munger, Smith), not personalised investment advice. The scores reflect how closely each stock matches each framework's documented criteria — they are not buy/hold/sell recommendations. Always do your own research and consult a licensed financial adviser for personalised advice.

Stock comparison

Jeena Sikho Lifecare Limited

JSLL.BO$69.36BHealthcare Market cap, Sector

Royalty Pharma

RPRX$30.5BHealthcare Market cap, Sector

Overall winner

Jeena Sikho Lifecare Limited

JSLL.BO 70 RPRX

Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.

Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.

Fit scores by strategy

JSLL.BO7wins

0winsRPRX

Warren Buffett

84B

C64

Benjamin Graham

87A

B82

Philip Fisher

92A

C63

Peter Lynch

66C

D58

Joel Greenblatt

75B

F38

Charlie Munger

91A

C66

Terry Smith

95A

D56

Side-by-side metrics

Metric	JSLL.BO	RPRX
Market cap	Winner: $69.36B	$30.5B
P/E (TTM)	33.2x	27.6x Winner
EV/EBIT	24.1x	19.9x Winner
ROIC (TTM)	Winner: 39.15%	8.43%
Gross margin	88.58%	99.95% Winner
Net margin	27.68%	33.91% Winner
Revenue CAGR 5y	Winner: 57.81%	0.96%
EPS CAGR 5y	Winner: 86.67%	11.83%
Debt / Equity	Winner: 0.3x	1.3x
Dividend yield	-	1.72%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

JSLL.BO leads on

Revenue CAGR 5y57.81%vs 0.96%+98%
EPS CAGR 5y86.67%vs 11.83%+86%
Debt / Equity0.3xvs 1.3x+79%
ROIC (TTM)39.15%vs 8.43%+78%

RPRX leads on

Net margin33.91%vs 27.68%+18%
EV/EBIT19.9xvs 24.1x+17%
P/E (TTM)27.6xvs 33.2x+17%
Gross margin99.95%vs 88.58%+11%

More like JSLL.BO

JSLL.BO vs JSLL.NS JSLL.BO vs 4728.TWO JSLL.BO vs CAMX.ST JSLL.BO vs PME.AX

More like RPRX

RPRX vs JSLL.NS RPRX vs 4728.TWO RPRX vs CAMX.ST RPRX vs PME.AX

Read the full Buffett-Brain analysis for JSLL.BO Read the full Buffett-Brain analysis for RPRX

Related on invest-like

Strongest Moat Highest ROIC Warren Buffett strategy Economic Moat

Key terms in this analysis

ROIC Free Cash Flow (FCF)Economic Moat P/E Ratio Margin of Safety Quality Score

Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.

Side-by-side metrics

Metric	JSLL.BO	RPRX
Market cap	Winner: $69.36B	$30.5B
P/E (TTM)	33.2x	27.6x Winner
EV/EBIT	24.1x	19.9x Winner
ROIC (TTM)	Winner: 39.15%	8.43%
Gross margin	88.58%	99.95% Winner
Net margin	27.68%	33.91% Winner
Revenue CAGR 5y	Winner: 57.81%	0.96%
EPS CAGR 5y	Winner: 86.67%	11.83%
Debt / Equity	Winner: 0.3x	1.3x
Dividend yield	-	1.72%

Where each one wins

The metrics with the biggest gap between the two - sorted so the most decisive edges read first.

JSLL.BO leads on

Revenue CAGR 5y57.81%vs 0.96%+98%
EPS CAGR 5y86.67%vs 11.83%+86%
Debt / Equity0.3xvs 1.3x+79%
ROIC (TTM)39.15%vs 8.43%+78%

RPRX leads on

Net margin33.91%vs 27.68%+18%
EV/EBIT19.9xvs 24.1x+17%
P/E (TTM)27.6xvs 33.2x+17%
Gross margin99.95%vs 88.58%+11%